Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 28:2018:9185485.
doi: 10.1155/2018/9185485. eCollection 2018.

Buyang Huanwu Decoction Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats via Downregulation of Related Protein and Gene Expression

Xuan Wang  1   2 , Xia Li  1 , Li-Na Wang  1 , Jing-Juan Pan  3 , Xue Yang  1 , Yang-Lin Wei  1   2
Affiliations

Buyang Huanwu Decoction Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats via Downregulation of Related Protein and Gene Expression

Xuan Wang et al. Evid Based Complement Alternat Med. .

Abstract

Little is known about the effects of Buyang Huanwu decoction on pulmonary fibrosis. Herein, 144 healthy SD rats were randomly divided into six groups: blank control group (B), model control group (M), positive medicine control group (Mp), and high-, moderate-, and low-dose Buyang Huanwu decoction groups (Hd, Md, and Ld). A pulmonary fibrosis model was established by endotracheal injection of bleomycin. On the second day of modeling, the corresponding saline, methylprednisolone suspension, and the three doses of Buyang Huanwu decoction were used to treat the 6 groups of rats by intragastric administration for 7, 14, and 28 consecutive days. After 7, 14, and 28 days of treatment, the mRNA expression of CTGF and AKT, the protein level of CTGF, p-AKT, and collagen types I and III were tested. Finally, we found that the serum collagen type I and III level in Hd, Md, and Ld rats on the 14th and 28th day and the collagen type I and III level in Hd rats on 7th day were significantly lower than in M rats (P < 0.01). The protein level of p-AKT and CTGF in Hd and Md rats on the 7th and 14th days and the protein level of p-AKT in Hd rats on the 28th day were lower than in M rats (P < 0.01, P < 0.05). The level of CTGF mRNA in Hd, Md, and Ld rats and the level of AKT mRNA in Hd and Md rats on the 7th, 14th, and 28th days and the expression level of AKT mRNA in Ld rats on the 14th and 28th days were significantly lower than in M rats (P < 0.01). The study suggests that Buyang Huanwu decoction alleviated pulmonary fibrosis of rats by improvement of lung tissue morphology, low level of serum collagen types I and III, and the reduced expression of CTGF and p-AKT protein, which might be a result of its downregulated expression of CTGF and AKT mRNA levels.

PubMed Disclaimer

Figures

Figure 1
Figure 1
M: the model control group that has been induced into pulmonary fibrosis and treated by 0.9% normal saline. Hd: the high-dose Buyang Huanwu decoction group that is treated by high-dose Buyang Huanwu decoction.
Figure 2
Figure 2
The level of collagen type I. B: the blank control group that is not induced into pulmonary fibrosis. M: the model control group that has been induced into pulmonary fibrosis and treated by 0.9% normal saline. Mp: the positive medicine control group that is treated by methylprednisolone. Hd: the high-dose Buyang Huanwu decoction group that is treated by high-dose Buyang Huanwu decoction. Md: the moderate-dose Buyang Huanwu decoction group that is treated by moderate-dose Buyang Huanwu decoction. Ld: the low-dose Buyang Huanwu decoction group that is treated by low-dose Buyang Huanwu decoction.
Figure 3
Figure 3
The level of collagen type III. B: the blank control group that is not induced into pulmonary fibrosis. M: the model control group that has been induced into pulmonary fibrosis and treated by 0.9% normal saline. Mp: the positive medicine control group that is treated by methylprednisolone. Hd: the high-dose Buyang Huanwu decoction group that is treated by high-dose Buyang Huanwu decoction. Md: the moderate-dose Buyang Huanwu decoction group that is treated by moderate-dose Buyang Huanwu decoction. Ld: the low-dose Buyang Huanwu decoction group that is treated by low-dose Buyang Huanwu decoction.
Figure 4
Figure 4
The expression level of p-AKT. Determination of p-AKT and CTGF protein expression level by western blot. Compared with the B group (∗∗P < 0.01); compared with the M group (#P < 0.05, ##P < 0.01); compared with the Mp group (□P < 0.05, □□P < 0.01). B: the blank control group that is not induced into pulmonary fibrosis. M: the model control group that has been induced into pulmonary fibrosis and treated by 0.9% normal saline. Mp: the positive medicine control group that is treated by methylprednisolone. Hd: the high-dose Buyang Huanwu decoction group that is treated by high-dose Buyang Huanwu decoction. Md: the moderate-dose Buyang Huanwu decoction group that is treated by moderate-dose Buyang Huanwu decoction. Ld: the low-dose Buyang Huanwu decoction group that is treated by low-dose Buyang Huanwu decoction.
Figure 5
Figure 5
The expression level of CTGF. Determination of p-AKT and CTGF protein expression level by western blot. Compared with the B group (∗P < 0.05, ∗∗P < 0.01); compared with the M group (#P < 0.05, ##P < 0.01); compared with the Mp group (□□P < 0.01). B: the blank control group that is not induced into pulmonary fibrosis. M: the model control group that has been induced into pulmonary fibrosis and treated by 0.9% normal saline. Mp: the positive medicine control group that is treated by methylprednisolone. Hd: the high-dose Buyang Huanwu decoction group that is treated by high-dose Buyang Huanwu decoction. Md: the moderate-dose Buyang Huanwu decoction group that is treated by moderate-dose Buyang Huanwu decoction. Ld: the low-dose Buyang Huanwu decoction group that is treated by low-dose Buyang Huanwu decoction.
Figure 6
Figure 6
The western blot test results on the 7th day. B: the blank control group that is not induced into pulmonary fibrosis. M: the model control group that has been induced into pulmonary fibrosis and treated by 0.9% normal saline. Mp: the positive medicine control group that is treated by methylprednisolone. Hd: the high-dose Buyang Huanwu decoction group that is treated by high-dose Buyang Huanwu decoction. Md: the moderate-dose Buyang Huanwu decoction group that is treated by moderate-dose Buyang Huanwu decoction. Ld: the low-dose Buyang Huanwu decoction group that is treated by low-dose Buyang Huanwu decoction.
Figure 7
Figure 7
The western blot test results on the 14th day. B: the blank control group that is not induced into pulmonary fibrosis. M: the model control group that has been induced into pulmonary fibrosis and treated by 0.9% normal saline. Mp: the positive medicine control group that is treated by methylprednisolone. Hd: the high-dose Buyang Huanwu decoction group that is treated by high-dose Buyang Huanwu decoction. Md: the moderate-dose Buyang Huanwu decoction group that is treated by moderate-dose Buyang Huanwu decoction. Ld: the low-dose Buyang Huanwu decoction group that is treated by low-dose Buyang Huanwu decoction.
Figure 8
Figure 8
The western blot test results on the 28th day. B: the blank control group that is not induced into pulmonary fibrosis. M: the model control group that has been induced into pulmonary fibrosis and treated by 0.9% normal saline. Mp: the positive medicine control group that is treated by methylprednisolone. Hd: the high-dose Buyang Huanwu decoction group that is treated by high-dose Buyang Huanwu decoction. Md: the moderate-dose Buyang Huanwu decoction group that is treated by moderate-dose Buyang Huanwu decoction. Ld: the low-dose Buyang Huanwu decoction group that is treated by low-dose Buyang Huanwu decoction.
Figure 9
Figure 9
The gene expression level of AKT mRNA. Determination of CTGF and AKT mRNA expression level by RT-PCR. Compared with the B group (∗P < 0.05, ∗∗P < 0.01); compared with the M group (##P < 0.01). B: the blank control group that is not induced into pulmonary fibrosis. M: the model control group that has been induced into pulmonary fibrosis and treated by 0.9% normal saline. Mp: the positive medicine control group that is treated by methylprednisolone. Hd: the high-dose Buyang Huanwu decoction group that is treated by high-dose Buyang Huanwu decoction. Md: the moderate-dose Buyang Huanwu decoction group that is treated by moderate-dose Buyang Huanwu decoction. Ld: the low-dose Buyang Huanwu decoction group that is treated by low-dose Buyang Huanwu decoction.
Figure 10
Figure 10
The gene expression level of CTGF mRNA. Determination of CTGF and AKT mRNA expression level by RT-PCR. Compared with the B group (∗∗P < 0.01); compared with the M group (##P < 0.01). B: the blank control group that is not induced into pulmonary fibrosis. M: the model control group that has been induced into pulmonary fibrosis and treated by 0.9% normal saline. Mp: the positive medicine control group that is treated by methylprednisolone. Hd: the high-dose Buyang Huanwu decoction group that is treated by high-dose Buyang Huanwu decoction. Md: the moderate-dose Buyang Huanwu decoction group that is treated by moderate-dose Buyang Huanwu decoction. Ld: the low-dose Buyang Huanwu decoction group that is treated by low-dose Buyang Huanwu decoction.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fernandez I. E., Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. The Lancet. 2012;380(9842):680–688. doi: 10.1016/S0140-6736(12)61144-1. - DOI - PubMed
    1. Mojiri-Forushani H., Hemmati A. A., Dehghani M. A., Malayeri A. R., Pour H. H. Effects of herbal extracts and compounds and pharmacological agents on pulmonary fibrosis in animal models: a review. Journal of Integrative Medicine. 2017;15(6):433–441. doi: 10.1016/S2095-4964(17)60363-7. - DOI - PubMed
    1. Raghu G., Collard H. R., Egan J. J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidencebased guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine. 2011;183(6):788–824. - PMC - PubMed
    1. Ley B., Collard H. R., King T. E., Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine. 2011;183(4):431–440. doi: 10.1164/rccm.201006-0894CI. - DOI - PubMed
    1. Xu X., Dai H., Geng J., et al. Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase. Laboratory Investigation. 2015;95(8):846–859. doi: 10.1038/labinvest.2015.68. - DOI - PubMed

LinkOut - more resources